Bone Therapeutics Secures EUR 11.0 Million Financing

Bone Therapeutics secured financing of EUR 11.0 million (~USD $12.0 million). Funds will support late-stage clinical development of ALLOB and JTA-004.

JTA-004 is an off-the-shelf protein solution that is entering Phase III development to treat pain from knee osteoarthritis, while the ALLOB allogeneic cell therapy platform technology has...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us